

Past, Present and Future

Rationale for a Global Initiative

There is an increasing prevalence of kidney disease worldwide. The complications and problems of patients with kidney disease are universal.

Resources may vary, but the science and evidence-based care of patients with kidney disease are independent of geographical location or national borders.


There is room for improving international cooperation in the development, dissemination, and implementation of evidence-based care of CKD patients worldwide.

GLOBAL GUIDELINES INTIATIVE Background of the Initiative

Preliminary exploratory meeting July 2002, Copenhagen

Global Coordinating Board January 2003, London

Coordinating Board meeting December 2003, Amsterdam



KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES



MISSION STATEMENT

Improve the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration and integration of initiatives to develop and implement clinical practice guidelines



KDIGO Board of Directors - 2006

Garabed Eknoyan, USA

Co-Chair

Norbert Lameire, Belgium Co-Chair

Nathan Levin, USA

Mona Al-Rukhaimi, UAE

Phillip Li, Hong Kong

Sharon Andreoli, USA

Francesco Locatelli, Italy

Adeera Levin, Canada

Mustafa Arici, Turkey

Alison MacLeod, UK

Kamal Badr, Lebanon

Donna Mapes, USA

Rashad Barsoum, Egypt

Linda McCann, USA

Gavin J. Becker, Australia

Sergio Mezzano, Chile

Ezequiel Bellorin, Venezuela

Sarala Naicker, South Africa

Fred Brown, USA

Brian Pereira, USA

Emmanuel Burdman, Brazili

Miguel Riella, Brazil

Jorge Cannata, Spain

Jerome Rossert, France

Jeremy Chapman, Australia

Yusuke Tsukamoto, Japan

Fernando Carrera, Portugal

Raymond Vanholder, Belgium

Bruce Culleton, Canada

Yves Vanrenterghem, Belgium

Jean-Yves DeVos, Belgium

Rowan Walker, Australia

Kai-Uwe Eckardt, Germany

Hyan Wang, China

Knut Erbin, Germany

Christopher Wanner, Germany

Dennis Fouque, France

Jan Weening, Netherlands


Vivekanand Jha, India

David Wheeler, UK

Michelle Josephson, USA

Andre Wiecek, Poland
Carmine Zoccali, Italy

Bertram Kasiske, USA



KDIGO - Executive Committee 2006

Co-Chairs: Garabed Eknoyan, USA

Norbert Lameire, Belgium

Members: Emmanuel Burdmann, Brazil

Kai-Uwe Eckardt, Germany

Adeera Levin, Canada

Nathan Levin, USA

Francesco Locatelli, Italy


Alison Macleod, UK

Sharon Moe, USA

Raymond Vanholder, Belgium

Rowan Walker, Australia

Hyan Wang, China



KDIGO - Work Groups 2006

Evidence Rating — Alison MacLeod, UK

Katrin Uhlig, USA

Database Website — Raymond Vanholder, Belgium Nathan Levin, USA

Implementation/ Regions with CPGs — Norbert Lameire, Belgium Francesco Locatelli, Italy

Implementation/ Regions without CPGs- Vivek Jha, Egypt

E. Burdmann, Brazil

CKD-MBD — Sharon Moe, USA Tilman Drüeke, France

Guideline Development Work Groups

Grading Evidence and Recommendations for Clinical Practice Guidelines. A Position Statement from KDIGO

Kidney Int 2006; 70:

KDIGO Projects for 2004 -...

- Core messages: Evidence Rating
- Database/Warehouse: is on the

Web at: KCIGO.Org

Try it, you will like it.

Raymond Vanholder, Belgium Nathan Levin, USA

Guideline Development Work Groups 2006

Hepatitis C -

David Roth, USA; Michel Jadoul, Belgium

CKD-MBD -

Sharon Moe, USA; Tilman Drüeke France

Transplant Recipient -

Bertram Kasiske, USA; Martin Zeier, Germany

KDIGO Projects for 2004-...

Controversies Conferences

WHAT DO WE KNOW

(Available Evidence)

WHAT CAN WE DO WITH WHAT WE KNOW

(Recommendations vs. Guidelines)

WHAT DO WE NEED TO KNOW

(Gaps in knowledge, Research questions)

1st KDIGO Controversies Conference

DEFINITION and CLASSIFICATION of CKD

Co-Chairs: Andrew Levey, USA
Kai-Uwe Eckardt, Germany

Amsterdam, November 16-17, 2004

Definition and Classification of Chronic Kidney Disease. A Position Statement from KDIGO

Kidney Int 67:2089-2100, 2005 www.kdigo.org

2nd KDIGO Controversies Conference

DEFINITION, EVALUATION& CLASSIFICATION of ROD

Co-Chairs: Sharon Moe, USA
Tilman Drüeke, France

Madrid, September 15-17, 2005

Definition, Evaluation, and Classification of Renal Osteodystrophy. A Position Statement from KDIGO

Kidney Int 69:1945-1953, 2006

CKD-MBD Projects for 2005 - ...

- PTH Assay Standardization
- Clinical Guide
- Controversies Conference:

Definition, Diagnosis and Classification of Renal Osteodystrophy

- Clinical Practice Guideline
- Bone Biopsy Quality Initiative

3rd KDIGO Controversies Conference

Care of the Kidney Transplant Recipient

Co-chairs: F. Delmonico, USA M. Zeier, Germany

Lisbon, Portugal February 2-4, 2006

Stage	Description	GFR (ml/min/1.73 m ²)	
1	Kidney damage with normal or ↑ GFR	≥ 90	
2	Kidney damage with mild ↓ GFR	60-89	
3	for transplant	30-59	
4	Severe ↓ GFR	15-29	
5	Kidney failure	< 15 (or dialysis)	

4th KDIGO Controversies Conference

CKD as a Global Health Problem: Approaches and Initiatives

Co-Chairs: Andrew Levy, Kai-Uwe Eckardt, Adeera Levin, Allan Collins, Meguid El-Nahas


October 12-14, 2006

Estimates of CKD (Stages 3 – 5) Prevalence Worldwide

Stages of CKD. U.S.				Stages 3-5 of CKD	
	N (1000s)	%		COUNTRY	%
1	5900	3.3	924/5/- /5//	US	4.7%
2	5300	3.0		UK	4.9%
3	7600	4.3		Netherlands	5.3%
4	400	0.2		Australia	11.2%
5	300	0.2		China	2.53%
			18/7/15 19 19		

Guesstimated Average ≈ 3 to 5.0 %

CKD as a Worldwide Public Health Problem Estimated Prevalence of CKD (Stages 3-5) in the World



Population 6.65 Billion CKD (Stages 3-5): $\approx 200 - 333$ million

SUMMARY

KDIGO Activities 2004 - 2006

- Controversies Conferences: CKD Classification, ROD, Transplant Recipient, CKD a Global Public Health Problem
- Position Statements: Burden of CKD, CKD Classification, ROD, Grading of Evidence, Care of the transplant recipient
- Clinical Practice Guidelines:


Hepatitis C

CKD-MBD

Transplant Recipient

Conclusion

The Past - December 2003





The Present - November 2006



The Future? - 2007



##